Trial Information

Summary: If the patient has Follicular Lymphoma and has not been treated previously for the disease, he/she may be eligible for this clinical trial.

Physicians are currently seeking subjects to participate in this open-labeled, randomized, two-dose, parallel group, phase II clinical research study of an investigational agent (ofatumumab). Patients in the trial will receive one of two possible doses of ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with CHOP.

Qualified subjects receive all study-related evaluations and procedures related to the study at no cost.

Inclusion Criteria:

• Patient with Follicular Lymphoma grade 1 - 3, stage III-IV, or Bulky disease stage II
• ECOG Performance Status of 0, 1, or 2
• Age = 18 years
• Following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study related activity is carried out

Exclusion Criteria:

• Any previous treatment for Follicular Lymphoma
• Clinical suspicion that the Follicular Lymphoma has transformed to aggressive lymphoma

There are additional inclusion and exclusion criteria that may be discussed with a study physician.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.